Your browser doesn't support javascript.
loading
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
Fencer, Maria G; Davis, Catherine H; Liu, Jieqi; Galan, Mark A; Spencer, Kristen R.
Affiliation
  • Fencer MG; Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
  • Davis CH; Rutgers New Jersey Medical School, Newark, USA.
  • Liu J; Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ, USA.
  • Galan MA; Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
  • Spencer KR; Rutgers Cancer Institute of New Jersey, New Brunswick, USA.
J Investig Med High Impact Case Rep ; 10: 23247096221129470, 2022.
Article in En | MEDLINE | ID: mdl-36541195
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Year: 2022 Type: Article